Background: Cyclodextrins (CDs) are versatile excipients with an essential role in drug delivery, as they can form non-covalently bonded inclusion complexes (host-guest complexes) with several drugs either in solution or in the solid state. Methods: The main purpose of this publication was to carry out a state of the art of CDs as complexing agents in drug carrier systems. In this way, the history, properties and pharmaceutical applications of the CDs were highlighted with typical examples. The methods to enhance the Complexation Efficiency (CE) and the CDs applications in solid dosage forms were emphasized in more detail. Results: The main advantages of using these cyclic oligosaccharides are as follows: (1) to enhance solubility/ dissolution/ bioavailability of poorly soluble drugs; (2) to enhance drug stability; (3) to modify the drug release site and/or time profile; and (4) to reduce drug side effects (for example, gastric or ocular irritation). These compounds present favorable toxicological profile for human use and therefore there are various medicines containing CDs approved by regulatory authorities worldwide. On the other hand, the major drawback of CDs is the increase in formulation bulk, once the CE is, in general, very low. This aspect is particularly relevant in solid dosage forms and limits the use of CDs to potent drugs. Conclusion: CDs have great potential as drug carriers in Pharmaceutical Technology and can be used by the formulator in order to improve the drug properties such as solubility, bioavailability and stability. Additionally, recent studies have shown that these compounds can be applied as active pharmaceutical ingredients.

Background: Pharmacovigilance is vital for monitoring adverse drug reactions (ADRs) and ensuring drug safety. Traditional methods are slow and inconsistent, but artificial intelligence (AI), through automation and advanced analytics, improves efficiency and accuracy in managing increasing data complexity. Aim: To explore AI’s practical applications in pharmacovigilance, focusing on efficiency, process acceleration, and task automation. It also examines the use of an expert-defined Bayesian network for causality assessment in a Pharmacovigilance Centre, demonstrating its impact on decision-making. Method: A comprehensive literature narrative review was conducted in MEDLINE (via PubMed), Scopus, and Web of Science using a set of targeted keywords, including but not limited to “pharmacovigilance”, “artificial intelligence”, “adverse drug reactions” and “drug safety”. Relevant studies were analysed without restrictions on publication year or language. The search was carried out in January 2025. Results: AI has greatly improved pharmacovigilance by streamlining signal detection, surveillance, and ADR reporting automation. Techniques like data mining and automated signal detection have expedited safety signal identification, while duplicate detection has enhanced data precision in safety evaluations. AI has also refined real-world evidence analysis, deepening drug safety and efficacy insights. Predictive models now anticipate ADRs and drug-drug interactions, enabling proactive patient care. At a regional pharmacovigilance center, the implementation of an expert-defined Bayesian network has optimized causality assessment, reducing processing times from days to hours, minimizing subjectivity, and improving the reliability of drug safety evaluations. Conclusion: AI holds significant promise for enhancing pharmacovigilance practices, yet its practical application remains primarily confined to academic research, with integration hindered by data quality issues, regulatory barriers, and the need for more transparent algorithms.

Emulsions are the most common form of skin care products. However, these systems may exhibit some instability. Therefore, when developing emulsions for topical application it is interesting to verify whether they have suitable physical and mechanical characteristics and further assess their stability. The aim of this work was to study the stability of emulsion systems, which varied in the proportion of the emulsifying agent cetearyl alcohol (and) sodium lauryl sulfate (and) sodium cetearyl sulfate (LSX), the nature of the oily phase (decyl oleate, cyclomethicone or dimethicone) and the presence or absence of pumice (5% w/w). While maintaining the samples at room temperature, rheology studies, texture analysis and microscopic observation of formulations with and without pumice were performed. Samples were also submitted to an accelerated stability study by centrifugation and to a thermal stress test. Through the testing, it was found that the amount of emulsifying agent affects the consistency and textural properties such as firmness and adhesiveness. So, formulations containing LSX (5% w/w) and decyl oleate or dimethicone as oily phase had a better consistency and remained stable with time, so exhibited the best features to be used for skin care products.